以Tenoxicam注射途徑來治療風濕病痛

Tenoxicam used as a Parenteral Formulation for Acute Pain in Rheumatic Conditions

吾人進行臨床試驗來評估tenoxicam靜脈或肌肉注射途徑，在緩解風濕病痛的治療效果。總共有30個風濕病例，區分為兩組，一組15人接受靜脈注射，另一組15人肌肉注射。每天一次20 mg tenoxicam注射，連續3天。結果顯示，不論靜脈或肌肉注射，兩組病人對於關節疼痛的緩解皆有很好的療效，在統計學上，也無明顯的差異性。病人注射tenoxicam 後1小時疼痛開始緩解，且在第3小時，達到最大疼痛緩解。在副作用方面，僅有症狀輕微的皮膚癢、噁心及腹痛，佔總數10％，且沒有腸胃道出血。同時也沒有病人因為副作用而停藥。結論：由本次試驗，可知注射形式之tenoxicam對於急性風濕病痛能迅速緩解，且僅有輕微的副作用。

For the evaluation of acute pain relief in rheumatic conditions, parenteral form of tenoxicam, including intravenous (IV) and intramuscular (IM) forms were used to assess the clinical therapeutic effect. A total of 30 rheumatic patients enrolled into this study. Patients were classified into 2 groups, 15 patients receiving IV form and another 15 receiving IM form. After consecutive 3 days IV or IM tenoxicam treatment, the results showed good efficacy in both groups. The onset of joint pain relief was at 1 hour after tenoxicam injection and the maximal effect of joint pain relief reached at 3 hours later. The adverse effects of tenoxicam injection were mild and only 10 percent of patients experienced. Meanwhile, there were also no one to discontinue the drug for their adverse effects. In conclusion, tenoxicam 20 mg IV and IM can therefore be safely prescribed for the effective treatment of acute pain in rheuamtic conditions.